|
- Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous . . .
Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism However, uncertainty remains about the difference in bleeding risk between the two m
- The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
- Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia . . .
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of chemotherapy that is associated with bleeding, reduced relative dose intensity, and potentially worse outcomes No widely ava
- Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute . . .
Whether anticoagulation alone is an adequate treatment for acute, intermediate-risk pulmonary embolism is uncertain We conducted a multinational, adaptive-design trial with blinded outcome adjudic
- Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
Preclinical data indicate that inhaled treprostinil may be useful for the treatment of idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism, a premise that is supported by clinical
- Medical Management and Revascularization for Asymptomatic Carotid . . .
Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred management of asymptomatic carotid stenosis Whether adding revascularization t
- A Phase 3 Trial of Brepocitinib in Dermatomyositis
Brepocitinib is a first-in-class, oral, selective TYK2–JAK1 inhibitor that blocks cytokine signaling, which has been implicated in dermatomyositis In this phase 3, double-blind, randomized
- Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual Current disease-modifying therapies for multiple sclero
|
|
|